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2Agenda
 Work Group’s assessment of catch-up immunization safety data
 Clarification of CDC guidance
 Summary of Work Group considerations 
 Proposed text for policy options
3Work Group assessment: Safety of >1 dose of Tdap for 
catch-up immunization schedule
 Published studies reassuring 
–
–
Data limited
Includes an RCT comparing safety and immunogenicity of Tdap v. Td for catch-
up immunization schedule
 Available published and unpublished data on closely-spaced Tdap vaccines 
–
–
No concerning safety signal, including in pregnant women
Data sparse on safety of multiple doses of Tdap during a single pregnancy
 Need for continued safety monitoring 
Work Group consensus: Either Td or Tdap can be used for additional doses of the 
catch-up immunization schedule for persons ≥7 years, both in the general population 
and for pregnant women
4Clarification of CDC guidance: Tdap in persons aged 7–10 
years
 Current guidance: Children 7–10 years who receive Tdap inadvertently or for catch-up immunization 
should receive Tdap again at age 11–12 years 
 Questions from health departments, immunization programs, and providers about 10 year-olds who 
receive Tdap for school entry requirements 
 Both Tdap vaccines are now licensed to 10 years of age
 Clarification of guidance in children 7–10 years who receive a dose of Tdap: 
–
–
Children 7–9 years: receive adolescent Tdap at 11–12 years
Children aged ≥10 years: Tdap does not need to be repeated
 Similar changes made to inadvertent DTaP administration guidance
 Plan to include changes as “CDC Guidance” in Policy Note
5Should either Td or Tdap be allowed for use in settings where only Td is currently 
recommended for the decennial booster, tetanus prophylaxis for wound 
management, and the catch up immunization schedule?
Criteria Work Group Interpretation
Benefits and Harms • Increased flexibility for providers
• May be some additional benefit for pertussis control
• Not enough evidence to recommend Tdap preferentially replace Td
• No substantive safety concerns
Benefits outweighs potential harms
Values, Acceptability and 
Feasibility
• Providers value flexibility
• Evidence of widespread use of Tdap instead of Td 
Valued by stakeholders; change is acceptable and feasible
Resource Use • Tdap more expensive than Td
• Economic analyses limited by uncertainty in key parameters
Economic impact not a major consideration
6Policy options for ACIP consideration
Policy issue Work Group Interpretation
Either Td or Tdap can be used for the decennial Td 
booster We are in favor of the intervention
Either Td or Tdap can be used for tetanus prophylaxis in 
the setting of wound management We are in favor of the intervention
Either Td or Tdap can be used for additional doses of the 
catch-up immunization schedule for persons ≥7 years, 
including for pregnant women
We are in favor of the intervention
7Potential off-label recommendations
Proposed Policy Language
9Decennial Td booster and tetanus prophylaxis: Proposed 
language 
 Decennial booster in persons with documentation of previous Tdap (in persons 
aged 7–18 Years and ≥19 years): 
“To ensure continued protection against tetanus and diphtheria, booster doses of 
either Td or Tdap should be administered every 10 years throughout life.”
 Tetanus prophylaxis for wound management in persons with previous 
documentation of Tdap: 
“For nonpregnant persons with documentation of previous vaccination with Tdap, 
either Td or Tdap should be used if a tetanus toxoid–containing vaccine is indicated.”
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Catch-up immunization schedule: Proposed language, 
persons aged 7–18 years and ≥19 years
 Persons aged (7–18 years and ≥19 years) who have never been vaccinated against 
pertussis, tetanus, or diphtheria should receive a series of three tetanus and 
diphtheria toxoid-containing vaccines, which includes at least 1 dose of Tdap. The 
preferred schedule is a dose of Tdap, followed by a dose of either Td or Tdap at 
least 4 weeks afterward and another dose of either Td or Tdap 6 to 12 months later. 
Persons aged (7–18 years and ≥19 years) who are not fully immunized against 
pertussis, tetanus or diphtheria should receive 1 dose of Tdap (preferably the first) 
in the catch-up series; if additional tetanus toxoid–containing doses are required, 
either Td or Tdap vaccine can be used.
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Catch-up Immunization and Prevention of Obstetric and 
Neonatal Tetanus: Proposed language
 Proposed text: The risk of neonatal tetanus is minimal if a previously unimmunized 
woman has received at least 2 properly spaced doses of tetanus toxoid–containing 
vaccine during pregnancy; one of the doses administered during pregnancy should 
be Tdap, administered according to the current guidance. If more than one dose of 
a tetanus-toxoid containing vaccine is needed, either Td or Tdap vaccine can be 
used for those doses. She should complete the 3-dose primary series at the 
recommended intervals.
12
Summary: Proposed policy change
 Recommendations should be changed to allow either Td or Tdap vaccine to be used 
in situations where only Td vaccine is currently recommended for:
–
–
–
Decennial booster
Tetanus prophylaxis for wound management
Catch-up immunization schedule, including in pregnant women 
For more information, contact CDC
1-800-CDC-INFO (232-4636)
TTY:  1-888-232-6348    www.cdc.gov
The findings and conclusions in this report are those of the authors and do not necessarily represent the 
official position of the Centers for Disease Control and Prevention.
Questions?
Questions?
